Biographies

**Daniel Auclair, PhD**, is the Senior Vice President, Research, at the Multiple Myeloma Research Foundation. Prior to rejoining in 2013 the MMRF for whom he had managed the Multiple Myeloma Genomics Initiative from 2007-2010, Dr. Daniel Auclair worked at the Broad Institute of MIT and Harvard as a senior leader in the Cancer Program where he was involved with a wide range of academic and industry collaborations centered around cancer genomics and personalized medicine. Prior to this, he spent a decade in the pharmaceutical industry, most notably at Bayer Healthcare where he led a number of cancer drug discovery efforts. Dr. Auclair holds graduate and post-graduate degrees in Biochemistry and Nutrition from the University of Montreal and conducted postdoctoral studies at the Dana-Farber Cancer Institute/Harvard Cancer Center.

**Donald Berry, PhD**, is professor in the Department of Biostatistics of the University of Texas M.D. Anderson Cancer Center. He received his Ph.D. in statistics from Yale University and has held endowed faculty positions at Duke University and M.D. Anderson. He has designed and supervised the conduct of many innovative clinical trials, including adaptive Bayesian trials, in cancer and other diseases. A principal focus of his research is the use of biomarkers for learning which patients benefit from which therapies, based on genomics and phenotype. In particular, he designed and is a co-PI of I-SPY 2 and GBM-AGILE, Bayesian adaptive platform clinical trials in high-risk early breast cancer and glioblastoma multiforme, respectively. He has authored many books on biostatistics and over 400 peer-reviewed articles. He is a Thomson Reuters Highly Cited Researcher in recognition of ranking among the top 1% of most cited researchers in Clinical Medicine. He has received numerous research grants from the NIH and NSF and is Fellow of the American Statistical Association and of the Institute of Mathematical Statistics. He is founder and co-owner of Berry Consultants.

**Vishal Bhatnagar, MD**, is a Medical Officer in the Division of Hematology Products (DHP), within the Office of Hematology Oncology Products (OHOP), at the Food and Drug Administration. Prior to joining DHP, he earned his medical degree from the George Washington University. He completed his internship and residency in internal medicine at the University of Maryland Medical Center. He continued his training at the University of Maryland, where he completed his fellowship in hematology and oncology. Dr. Bhatnagar’s clinical and regulatory interests include multiple myeloma, immunoglobulin light chain amyloidosis, and Waldenstrom’s macroglobulinemia. He serves as a multiple myeloma scientific liaison within OHOP.
Amy Burd, PhD, is vice president of research strategy for The Leukemia & Lymphoma Society (LLS). Dr. Burd first began working with LLS in 2009 as senior director of LLS’s Therapy Acceleration Program, a strategic initiative through which LLS partners directly with biotechnology companies to help accelerate the development of promising therapies. In this role she managed due diligence process for identifying strategic partnerships. In her current role, Dr. Burd provides strategic planning and oversight for mission special initiatives. She also leads LLS’s Beat AML initiative, a significant multi-institution collaboration to change the paradigm of treatment and improve outcomes for patients with acute myeloid leukemia (AML). Dr. Burd also leads other special research initiatives and collaborations. Prior to joining LLS, Dr. Burd was oncology portfolio manager at Bayer Pharmaceuticals and consultant to small biotechnology companies. Dr. Burd earned her doctorate in pharmacology from University of Minnesota-Twin Cities and her Bachelor of Science degree from Ohio Northern University.

John C. Byrd, MD, is an internationally known researcher and clinical specialist in leukemia and other hematologic malignancies at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; he is also the head of the Division of Hematology. He is a University Distinguished Professor of Medicine and Medicinal Chemistry and holds the D. Warren Brown Chair in Leukemia Research. Dr. Byrd received his medical degree from the University of Arkansas for Medical Sciences. His education continued in hematology and oncology at Walter Reed Army Medical Center and Johns Hopkins University before moving to Columbus to join the faculty at Ohio State. Dr. Byrd has over 420 publications in the area of leukemia and experimental therapeutics research. He runs a highly translational laboratory focused on drug development in CLL and related lymphoproliferative disorders. He has been part of the successful development of multiple therapeutics in acute myeloid leukemia and chronic lymphocytic leukemia. Dr. Byrd is the co-Chair of the Leukemia Committee and Leukemia Correlative Science Committee in the Alliance for Clinical Trials in Oncology. He also is a member of the NCI Leukemia Steering Committee. Despite his passion for clinical and translational research, Dr. Byrd’s favorite day is Tuesdays, when he spends eight to 12 hours in the clinic providing care for patients. He receives continuous support from his wife Laura and two sons. He is a passionate Ohio State and University of Arkansas football fan, and in his spare time he enjoys freshwater fishing.

Gregory Daniel, PhD, MPH, is a Clinical Professor in Duke’s Fuqua School of Business and Deputy Director in the Duke-Robert J. Margolis Center for Health Policy at Duke University. Dr. Daniel directs the DC-based office of the Center and leads the Center’s pharmaceutical and medical device policy portfolio which includes developing policy and data strategies for improving development and access to innovative pharmaceutical and medical device technologies. This includes post-market evidence development to support increased value, improving regulatory science and drug development tools, optimizing biomedical innovation, and supporting drug and device payment reform. Dr. Daniel is also a Senior Advisor to the Reagan-Udall Foundation for the FDA and Adjunct Associate Professor in the Division of Pharmaceutical Outcomes and Policy at the UNC Eshelman School of Pharmacy. Previously, he was Managing Director for Evidence Development & Biomedical Innovation in the Center for Health Policy and Fellow in Economic Studies at the Brookings Institution and Vice President, Government and Academic Research at HealthCore (subsidiary of Anthem, Inc). Dr. Daniel’s research expertise includes utilizing electronic health data in designing research in health outcomes and pharmacoconomics, comparative effectiveness, and drug safety and pharmacoepidemiology. Dr. Daniel received a PhD in pharmaceutical economics, policy and outcomes from the University of Arizona, as well as an MPH, MS, and BS in Pharmacy all from The Ohio State University.
R. Angelo de Claro, MD, is a Clinical Team Leader with the Division of Hematology Products, Office of Hematology Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration. He received his M.D. degree (magna cum laude) in 1998 from the University of the Philippines. He completed his Internal Medicine residency at Baylor College of Medicine (Houston, TX), and his Hematology-Oncology fellowship at University of Washington (Seattle, WA). He joined FDA as a medical officer in 2010, and became a clinical team leader in 2012. Currently, he provides leadership to a team of clinical reviewers who review drug applications for benign and malignant hematology indications.

Jennifer Dickey, PhD, RAC, is a senior regulatory reviewer in the Office of In Vitro Diagnostics and Radiological Health (OIR) at the Center for Devices and Radiological Health (CDRH) in the Food and Drug Administration (FDA). Dr. Dickey leads the review of submissions in the Molecular Genetics Branch as part of the Division of Molecular Genetics and Pathology (DMGP). The Molecular Genetics Branch is responsible for reviewing a wide range of devices including next generation sequencing technologies and molecular techniques to detect genetic alterations associated with disease. Dr. Dickey was the lead reviewer for the recent clearance of the QuantideX BCR-ABL Assay for monitoring patients with CML. She additionally specializes in review of devices intended to aid in selection of therapy for patients with leukemia and other hematologic malignancies. Prior to her current position, Dr. Dickey was a reviewer in the Center for Drug Evaluation and Research (CDER) in the Office of Biotechnology Products. Dr. Dickey obtained her Ph.D. from Vanderbilt University and was a post-doctoral fellow at the National Cancer Institute.

Janet L. Franklin, MD, MPH, is an Executive Medical Director at Amgen Inc. and is the Global Development Lead for Blinatumomab. She has worked on a series of Hematology/Oncology drug development programs with increasingly levels of responsibilities during her 9 years at Amgen. She is a pediatric hematologist/oncologist by training and had an academic medicine career prior to her current industry work. Her interest in childhood leukemia and lymphoma diseases included clinical trial research, clinical practice and education of residents and fellows as the Clinical Director of the Leukemia/Lymphoma program at Childrens Hospital Los Angeles/USC School of Medicine. Janet was also an active contributor to the Children's Oncology Group. Janet received her MPH from University of Texas, Houston, School of Public Health and her MD from Georgetown University School of Medicine. She completed her pediatric residency training at Texas Children’s Hospital and her research immunology fellowship at Baylor College of Medicine. She completed her pediatric hematologyp/ oncology fellowship at the NCI Pediatric Branch.

Nicole Gormley, MD, completed fellowship training in both hematology and critical care at the National Institutes of Health. While at NIH, her research involved investigation of the non-infectious pulmonary complications that occur after hematopoietic stem cell transplant and served as the principal investigator of clinical trials of a novel treatment for bronchiolitis obliterans in the post-transplant setting. After her training, Dr. Gormley served as the Deputy Clinical Director at the National Heart, Lung and Blood Institute before joining the Food and Drug Administration. Dr. Gormley currently works in the Division of Hematology Products at the FDA as an Acting Clinical Team Leader and serves as a scientific liaison for multiple myeloma in the Office of Hematology and Oncology Products. In these roles, Dr. Gormley has actively engaged the multiple myeloma community on the development of novel endpoints, including minimal residual disease. Dr. Gormley continues clinical research and practices at the NIH.
Antje Hoering, PhD, is President and Chief Executive Officer of Cancer Research And Biostatistics, a Seattle-based non-profit cancer research organization with expertise in designing, managing and analyzing oncology clinical trials. She presently serves as the lead statistician for the SWOG Myeloma Committee and is an active member of the Myeloma Steering Committee for the National Clinical Trials Network. Dr. Hoering also serves as the primary lead statistician of the Myeloma Institute at the University of Arkansas for Medical Sciences and is the Director of the Biostatistics Core for a SPORE grant funded through the Sarcoma Alliance for Research Through Collaboration. She is an associate editor of the Statistics in Biopharmaceutical Research journal and co-editor of the third edition of the Handbook of Statistics in Clinical Oncology. Dr. Hoering serves as a consultant on a variety of industry sponsored studies, including a phase III registration trial and has served as the biostatistics representative for Type B and pre-NDAs meetings with the FDA. Dr. Hoering holds affiliate appointments at the Fred Hutchinson Cancer Research Center and the Biostatistics Department of the University of Washington.

Christopher S. Hourigan, BM, BCh, BA, MSc, DPhil, FACP, is Chief of the Myeloid Malignancies Section in the Hematology Branch of the National Heart, Lung and Blood Institute at the National Institutes of Health. He received his medical degree from Oxford University Medical School and his D.Phil. in Human Immunology from the Weatherall Institute of Molecular Medicine, also at Oxford University. He completed residency training at Guy’s and St. Thomas’ Hospitals in London and the Johns Hopkins Bayview Medical Center in Baltimore where he was inducted into Alpha Omega Alpha and received the Patrick Murphy Award for resident teaching. He remained at Johns Hopkins for both clinical (Medical Oncology) and research (Cancer Immunology) postdoctoral fellowships at the Sidney Kimmel Comprehensive Cancer Center, where he was also part-time Assistant Professor of Oncology. He is board certified in Internal Medicine, Hematology and Medical Oncology and a Fellow of the American College of Physicians. Dr. Hourigan was recruited to the NIH in 2012 to establish the Myeloid Malignancies Section with a focus on the “Detection, prevention and treatment of Acute Myeloid Leukemia relapse, in particular the use of novel immunotherapy”. His work in the laboratory focuses on molecular methods for high sensitivity detection of residual AML, and clinically on the use of immunotherapy to prevent and treat AML relapse.

Rod Humerickhouse, MD, PhD, is a medical oncologist and pharmacologist with over 20 years of experience in clinical drug development. Currently, he is a Group Project Leader in Oncology Development at AbbVie, where he directs the Venclexta/venetoclax program. Throughout his career, Dr. Humerickhouse has been engaged in early drug development with an emphasis on translational science. He has designed and led numerous early stage clinical trials implementing the use of novel pharmacodynamic biomarkers and tumor biomarkers to guide development decisions. With a more recent emphasis in hematologic malignancies Dr. Humerickhouse has been working with a cross-functional team at AbbVie and with external collaborators to define innovative approaches to establish MRD and other molecular endpoints as key endpoints in clinical trials and as endpoints to be used for patient management.
Ola Landgren, MD, PhD, is Professor of Medicine and Chief Attending Physician of the Myeloma Service at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, NY. Dr. Landgren is one of the world leaders in the field of early treatment strategies and molecular- and cell-based monitoring of minimal residual disease (MRD) detection in multiple myeloma and its precursor states. He leads a translational research program at MSKCC designed to discover new treatment paradigms integrating modern therapy and novel MRD assays. Dr. Landgren has designed and led the definitive study showing that all multiple myeloma patients are preceded by a precursor stage. As part of his ongoing research program, he is studying molecular mechanisms underlying the trajectory from precursor to full-blown multiple myeloma with the goal to develop of treatment strategies aiming to delay, prevent, and ultimately define a cure for multiple myeloma. Dr. Landgren has published over 250 peer-reviewed publications and he is a frequently invited speaker at national and international hematology conferences. He serves on several research committees and editorial boards for scientific journals.

Richard Little, MD, is a Senior Investigator at the National Cancer Institute, Division of Cancer Treatment and Diagnosis. As the Section Head for Blood and AIDS-related Cancers in the Clinical Investigations Branch of the Cancer Therapy Evaluation Program (CTEP), he oversees and coordinates the clinical trials portfolio for NCI National Clinical Trials Network (NCTN) in hematologic cancers. Minimal residual disease across hematologic cancers has become an increasingly important biomarker for clinical investigation. CTEP, the NCI Biometric Research Program, and the NCI Cancer Diagnosis Program have focused considerable attention, as part of the NCI Precision Medicine Initiative, on biomarker development, evaluation, and interpretation. Dr. Little collaborates with experts in these programs and in the US cooperative groups to design statistically rigorous clinical trials that leverage the science of minimal residual disease to define the clinical utility of this biomarker. Dr. Little has conducted clinical research at the NCI for over 2 decades, primarily in hematologic cancers associated with HIV infection. He serves on the NCI steering committees for leukemia, lymphoma and myeloma, as well as committees for evaluating biospecimens banking and research.

Aaron Logan, MD, PhD, is an Assistant Professor of Clinical Medicine in the Division of Hematology and Blood and Marrow Transplantation at the University of California, San Francisco. Dr. Logan has published widely on the use of next-generation sequencing-based quantification of measurable residual disease (MRD) in various hematologic malignancies, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. Dr. Logan’s research interests focus on the application of high-throughput sequencing of immunoreceptor genes to quantify MRD in lymphoid malignancies, quantify B and T cell immune reconstitution after transplantation, and to quantify and track malignancy-, pathogen-, and autoantigen-targeted immune responses. Dr. Logan has a special clinical research interest in developing models for preemptive treatment of relapse based on progression of MRD prior to fulminant relapse.
Sumithra Mandrekar, PhD, is currently Professor of Biostatistics and Oncology at the Mayo Clinic, Rochester MN; and Associate Director of the Biostatistics Shared Resource of the Mayo Clinic Cancer Center. Her primary collaborative areas are lung cancer and leukemia. She is the faculty statistician for the national adjuvant lung cancer trial, ALCHEMIST, which is part of the NCI precision medicine initiative. Her primary research interests include adaptive dose-finding trial designs for Phase I trials, designs for predictive biomarker validation, and general clinical trial methodology related to identification of alternative Phase II cancer clinical trial endpoints. Dr. Mandrekar has co-authored over 110 original papers; several book chapters and editorials; and has given numerous lectures, invited presentations and workshops on these topics. She is a voting member on several national committees including the NCI thoracic malignancies steering committee, the NCI imaging steering committee, and the intergroup lung correlative sciences committee. She served on the program and education committees of ASCO from 2013-2016; and is the co-chair for the education committee of the Society for Clinical Trials for the 2017 joint SCT/ICTMC meeting. She is also an active reviewer for many clinical and statistical journals, including serving as the Biostatistics editor for the Journal of Thoracic Oncology.

Sharon McBain is Global Regulatory Leader, Senior Director for Janssen Oncology. With over 30 years of experience in industry, Sharon has a broad drug development background having worked in the non-clinical, clinical and regulatory fields in multiple therapy areas and for companies such as GSK and Biogen and was also previously a successful owner and director of her own consulting company. Since 1995 Sharon has worked in the regulatory arena and has led the successful registration of a large number of new medicinal products in Global markets. Relevant to today’s discussion on AML, Sharon supported the EU registration of DACOGEN on behalf of Janssen on a consultancy basis and joined the company permanently in January 2014. In addition to her product responsibility, Sharon leads the Janssen MRD (minimal residual disease) Working Group, whose strategic objective is to evaluate the potential surrogacy of MRD for overall survival in acute myeloid leukaemia (AML), as well as other haematological malignancies.
Mark McClellan, MD, PhD, is the Robert J. Margolis Professor of Business, Medicine, and Policy, and Director of the Duke-Margolis Center for Health Policy at Duke University with offices at Duke and in Washington DC. The new Center will support and conduct research, evaluation, implementation, and educational activities to improve health policy and health, through collaboration across Duke University and Health System, and through partnerships between the public and private sectors. It integrates the social, clinical, and analytical sciences to integrate technical expertise and practical capabilities to develop and apply policy solutions that improve health and the value of health care locally, nationally, and worldwide. Dr. McClellan is a doctor and an economist, and his work has addressed a wide range of strategies and policy reforms to improve health care, including such areas as payment reform to promote better outcomes and lower costs, methods for development and use of real-world evidence, and more effective drug and device innovation. Before coming to Duke, he served as a Senior Fellow in Economic Studies at the Brookings Institution, where he was Director of the Health Care Innovation and Value Initiatives and led the Richard Merkin Initiative on Payment Reform and Clinical Leadership. He also has a highly distinguished record in public service and in academic research. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. These include the Medicare prescription drug benefit, Medicare and Medicaid payment reforms, the FDA’s Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care. Dr. McClellan is the founding chair and a current board member of the Reagan-Udall Foundation for the FDA, is a member of the National Academy of Medicine and chairs the Academy’s Leadership Council for Value and Science-Driven Health care, co-chairs the guiding committee of the Health Care Payment Learning and Action Network, and is a research associate at the National Bureau of Economic Research. He has also previously served as a member of the President’s Council of Economic Advisers and senior director for health care policy at the White House, and as Deputy Assistant Secretary for Economic Policy at the Department of the Treasury. He was previously an associate professor of economics and medicine with tenure at Stanford University, and has twice received the Kenneth Arrow Award for Outstanding Research in Health Economics.

Lisa McShane, PhD, is a Mathematical Statistician in the Biometric Research Branch at the U.S. National Cancer Institute (NCI) where she advises programs in the Division of Cancer Treatment and Diagnosis on matters relating to development and use of tumor markers for prognosis, therapy selection, and disease-monitoring. She holds a Ph.D. in Statistics from Cornell University and is a Fellow of the American Statistical Association. Her statistical research interests include biomarker-based clinical trial design, analysis methods for high-dimensional genomic data, multiple comparisons methods, surrogate endpoints, measurement error adjustment methods, and biomarker assay analytical performance assessment. Dr. McShane has been a statistical collaborator in numerous studies examining molecular profiles of a variety of tumor types. She has served as a member of Institute of Medicine Committee for Management of the Air Force Health Study Data and Specimens, Consensus Committee on Management of the Air Force Health Study Data and Specimens-Report to Congress, and Committee on the State of the Science in Ovarian Cancer Research. She co-led the efforts to develop “Reporting guidelines for tumor marker prognostic studies (REMARK)” and “Criteria for the use of omics-based predictors in clinical trials.” Dr. McShane is an author on more than 100 publications in statistical and biomedical journals and co-author of the book “Statistical Design and Analysis of DNA Microarray Investigations.”
Carol Preston is a Patient Power host with over 30 years of experience in communications. She worked as a journalist and talk show host for 25 years. With her interest in medical issues, Carol has worked with scientists and physicians on a wide range of medical conditions including cancer-related treatments, cardiovascular health, metastatic breast cancer and others. Carol received her MS and BS degrees from Syracuse University in New York, and the AP and UPI have honored Carol for her documentary on Holocaust survivors. She has lectured on media at George Washington University and has written Congressional testimony and speeches for C-level executives. Carol served on the board for the organization Bread for the City in Washington, DC for eight years and remains active with the organization. First diagnosed in 2006, Carol is a ten-year CLL survivor. She is married and has two grown sons.

Donna Przepiorka, MD, PhD, is an Acting Clinical Team Leader in the Division of Hematology Products at the US Food and Drug Administration.

Jerald Radich, MD, is a Member of the Clinical Research Division, the Director the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center, and Professor of Medicine at the University of Washington School of Medicine. He is Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, co-chair of the NCI/NIH Leukemia Steering Committee, and is on the Board of Scientific Counselors, NIH Genome Research Institute. He is the Chair of the CML Committee of the National Comprehensive Cancer Network, a member of the European Leukemia Network CML committees, and is on the Scientific Board of the International CML Foundation and the Max Foundation. Dr. Radich’s laboratory work centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia.

David Alan Rizzieri, MD, is a Professor of Medicine at the Duke University Medical Center and a member of the Duke Cancer Institute. As a translational researcher, he has focused his efforts on developing new therapies for patients with leukemia or lymphoma. David is a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and the ALLIANCE (formerly CALGB) Leukemia Core Committee. He serves as chair or co-chair of multiple ALLIANCE lymphoma/ leukemia trials, the most recent being the last 2 national studies for Burkitt’s lymphoma, as well as the recent AML intergroup study. He has led his team’s novel approaches for the care of patients using non-myeloablative allogeneic therapy using haplo-identical, as well as matched donors. This work is currently being extended with post-transplant graft manipulation studies focused on manipulating Natural Killer cell activity. David has also led the first in human studies targeting acute myelogenous leukemia by linking diphtheria to a small molecule targeting the IL-3 receptor (now in phase 3). He serves on various NIH/NHLBI grant review committees and is a member of ASH, ASCO, AACR, ASBMT, ASCI, and the ASH sub-committee on Government Affairs. He oversees the development and conduct of all clinical trials in adults with hematologic malignancies conducted in the Duke Cancer Institute. In recognition of this leadership and success in our clinical research efforts, David was fortunate to receive the NIH ‘Clinical Investigator Team Leadership Award’ in 2010.
Gail J. Roboz, MD, is Professor of Medicine and Director of the Clinical and Translational Leukemia Programs at the Weill Medical College of Cornell University and the New York Presbyterian Hospital in New York City. Dr. Roboz graduated summa cum laude from Yale University and received her medical degree from The Mount Sinai School of Medicine in New York, where she was elected to the Alpha Omega Alpha Honor Medical Society and achieved the highest academic standing in the graduating class. She completed Internship in internal medicine at The Beth Israel Hospital in Boston and Residency in internal medicine at the New York Presbyterian Hospital. Dr. Roboz was a Fellow in hematology and medical oncology at Weill Cornell/New York-Presbyterian Hospital and is board-certified in both specialties. She is a member of the American Society of Hematology and the American Society of Clinical Oncology. Her research interests are in developmental therapeutics for acute leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Dr. Roboz is the principal investigator on investigator-initiated and industry-sponsored clinical trials in these areas and has authored or coauthored many manuscripts and abstracts. She sits on the editorial boards of and acts as a reviewer for several journals, and has played an active role as a speaker and panelist at numerous regional, national, and international conferences. Dr. Roboz also serves on the Medical Advisory Board of the Aplastic Anemia and MDS International Foundation.

Daniel J. Sargent, PhD, is the Ralph S. and Beverly E Caulkins Professor of Cancer Research at the Mayo Clinic. He is the Group Statistician for the Alliance for Clinical Trials in Oncology, Director of Biostatistics Shared Resource at the Mayo Clinic Comprehensive Cancer Center, and Section Head for the Section of Cancer Center Statistics at Mayo Clinic. He leads multiple international data pooling and analysis consortia including ACCENT in adjuvant colon cancer and the prospective IDEA international pooled analysis testing the duration of therapy in stage III colon cancer. He has authored over 290 peer-reviewed manuscripts, book chapters, editorials, and letters.

Wendy Stock, MD, is a tenured Professor of Medicine and currently directs the leukemia program at the University of Chicago where she is also a co-leader of the University of Chicago Comprehensive Cancer Center’s Program in Hematopoiesis and Hematological Malignancies. At a national level, she serves as co-chair of the Leukemia and Leukemia Clinical and Correlative Sciences Committees in the Alliance, a NCI-sponsored clinical trials cooperative group that leads national and international trials in leukemia clinical research, and served as the first co-chair of the NCI national clinical trials network (NCTN) Leukemia Steering committee, the committee which sets the agenda for all NCI sponsored large phase II and III trials in leukemia in the United States. Dr. Stock is an expert in clinical and correlative laboratory research involving acute and chronic leukemias. Her focus has been to design biologically risk-adapted clinical trials for patients with acute leukemias, leading national trials for treatment of acute lymphoblastic leukemia (ALL) in adults and leading the University of Chicago Leukemia Program’s efforts to develop innovative early phase trials for patients with ALL and AML, including novel trials of allogeneic stem cell transplantation for these disorders. She has focused on identifying new biological prognostic factors in specific subsets of leukemia that lead to novel clinical trial design and has focused particularly on the clinical significance of molecular detection and monitoring of subclinical disease (or minimal residual disease) using quantitative molecular methods. Dr. Stock has published more than 160 peer-reviewed papers, reviews and book chapters and serves on the editorial boards of Blood, and the Journal of Clinical Oncology, and was recently appointed an Associate Editor of Blood Advances.
Nancy Valente, MD, is VP, Global Product Development Oncology and Head of Hematology Development at Genentech where she leads the clinical development of hematology medicines. A board certified hematologist and medical oncologist, she is focused on continuing to improve outcomes for people with diseases of the blood, including cancers and hemophilia. Dr. Valente, who has more than 16 years of industry experience, joined Genentech in 2003. She is responsible for clinical development strategy for an extensive hematology portfolio, with medicines that span diverse mechanisms such as antibodies, antibody drug conjugates, apoptosis, immune therapy, and signaling. She oversees a team of 60 medical directors and clinical scientists located at three global sites in California, England and Switzerland. During her time at Genentech, she has overseen the development programs for Rituxan, Gazyva, the first medicine with Breakthrough Designation to be approved by the FDA, and more recently Venclexta, a first-in-class pro apoptotic therapy. Previously, Dr. Valente held positions at Coulter Pharmaceutical and Anosys, Inc., leading the Phase I/III development of biologic therapeutics (antibodies and vaccines) for solid tumors and hematological malignancies. Dr. Valente started her career as a practicing oncologist at the University of California San Francisco (UCSF) where she specialized in breast cancer as UCSF faculty. She received her medical degree from the University of Missouri and completed internal medicine training at Oregon Health Sciences University, followed by fellowships in hematology at Stanford University and oncology at UCSF. Dr. Valente has published research in hematology, solid tumors and immunotherapy in leading scientific journals and is an active member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Society of Hematology.

Ashley Ward, MD, is a medical officer in the Office of Oncology and Hematology Products at the U.S. Food and Drug Administration. Her work focuses on the evaluation of investigational new drug applications and marketing applications for drugs for the treatment of benign and malignant hematologic disorders, and she is the scientific liaison for Acute Lymphoblastic Leukemia. Previously, Dr. Ward was an assistant professor at the University of California, San Francisco (UCSF), where she cared for patients, taught medical students, residents, and fellows, and studied the role of individual Ras effector pathways in the development of myeloid malignancies. She also spent several years as a medical director in the early clinical development group at Genentech, where she led the development teams for several small molecules and antibody-drug conjugates through early phase testing for hematologic malignancies and breast cancer. Dr. Ward received her BA in Biology from Swarthmore College and her medical degree from Washington University School of Medicine. She completed her residency and chief residency at St. Louis Children’s Hospital, and her fellowship in pediatric hematology and oncology at the University of California, San Francisco.